{"version":"1.0","provider_name":"DelveInsight Business Research","provider_url":"https:\/\/www.delveinsight.com\/blog","title":"Pharma News for Sarepta, Astellas, SiSaf, ImmPACT Bio, Otsuka","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"GsaTwgVb1V\"><a href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sarepta-astellas-sisaf-otsuka\">Sarepta Therapeutics\u2019s SRP-9001 Gene Therapy; FDA Approves Astellas\u2019 VEOZAH; FDA Orphan Drug Designation and Rare Pediatric Disease Designation to SiSaf\u2019s siRNA Therapy SIS-101-ADO; FDA Grants Fast Track Designation to IMPT-314; FDA Approves First Drug for Agitation in People With Alzheimer\u2019s Disease; FDA Accepted the CytoAgents\u2019 IND Application for CTO1681<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sarepta-astellas-sisaf-otsuka\/embed#?secret=GsaTwgVb1V\" width=\"600\" height=\"338\" title=\"&#8220;Sarepta Therapeutics\u2019s SRP-9001 Gene Therapy; FDA Approves Astellas\u2019 VEOZAH; FDA Orphan Drug Designation and Rare Pediatric Disease Designation to SiSaf\u2019s siRNA Therapy SIS-101-ADO; FDA Grants Fast Track Designation to IMPT-314; FDA Approves First Drug for Agitation in People With Alzheimer\u2019s Disease; FDA Accepted the CytoAgents\u2019 IND Application for CTO1681&#8221; &#8212; DelveInsight Business Research\" data-secret=\"GsaTwgVb1V\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/16180543\/Pharma-News-and-Updates-for-Sarepta-Astellas-SiSaf-ImmPACT-Bio-Otsuka-CytoAgents-Lundbeck.png","thumbnail_width":772,"thumbnail_height":482,"description":"Sarepta's SRP-9001; Astellas\u2019 VEOZAH; SiSaf\u2019s SIS-101-ADO; ImmPACT's IMPT-314; CytoAgents\u2019 CTO1681; Otsuka's REXULTI\u00ae (brexpiprazole)"}